Fibroblast growth factor 21 (FGF21), aa29-209, human recombinant (rHuFGF21)

FGF-21 is a unique member of FGF super family that is reported to be primarily produced by the liver. FGF-21 has recently been shown to have beneficial effects on a variety of metabolic parameters, including glucose and lipid metabolism and insulin sensitivity in animal models and is thought to exert potent antidiabetic and lipid-lowering agent of obesity and type 2 diabetes mellitus. FGF-21 activity depends on membrane protein beta Klotho that physically complexes with various FGF receptors, thus conferring them the ability to bind FGF-21 and activate downstream signaling pathways. Recombinant human FGF-21 protein, fused to His-tag at N-terminus, was expressed in E. coli and purified by using conventional chromatography techniques. Endotoxin Level: < 1.0 EU per 1ug of protein (determined by LAL method), AA Sequence: MGSSHHHHHH SSGLVPRGSH MHPIPDSSPL LQFGGQVRQR YLYTDDAQQT EAHLEIREDG TVGGAADQSP ESLLQLKALK PGVIQILGVK, TSRFLCQRPD GALYGSLHFD PEACSFRELL LEDGYNVYQS EAHGLPLHLP GNKSPHRDPA PRGPARFLPL PGLPPAPPEP PGILAPQPPD , VGSSDPLSMV GPSQGRSPSY AS, Biological Activity: The ED50 for this effect is < 12 ng/ml, measured in a cell proliferation assay using NIH-3T3 cell (which corresponds to > 83,000 units/ml). Storage and Stability: For long-term storage, aliquot and store at -20°C. Aliquots are stable for at least 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.